[Form 4] Kura Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) senior vice president of finance and accounting Thomas Doyle reported equity transactions in a Form 4. On 11/13/2025, he acquired 24,967 shares of common stock at $0, raising his direct holdings to 134,796 shares. On 11/14/2025, he sold 4,539 shares of common stock at $11.1769 per share, leaving 130,257 shares held directly. The sale was described as a sell-to-cover for taxes tied to the vesting of performance-based restricted stock units granted on May 31, 2023, after a specified development milestone was met on November 13, 2025. He also holds 500 shares indirectly through his spouse's 401(k).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOYLE THOMAS JAMES

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Finance & Accounting

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		A		24,967	A	$0	134,796	D
Common Stock	11/14/2025		S(1)		4,539	D	$11.1769	130,257	D
Common Stock								500	I	spouse's 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.

	Teresa Bair, Attorney-in-fact for Thomas Doyle	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kura Oncology (KURA) report in this Form 4?

The filing shows that executive Thomas Doyle acquired 24,967 shares of Kura Oncology common stock on 11/13/2025 and sold 4,539 shares on 11/14/2025.

Who is the reporting person in the Kura Oncology (KURA) Form 4?

The reporting person is Thomas Doyle, who serves as SVP, Finance & Accounting at Kura Oncology, Inc..

At what prices were the Kura Oncology (KURA) insider transactions reported?

The acquisition of 24,967 shares of common stock was reported at $0, while the sale of 4,539 shares was reported at a price of $11.1769 per share.

How many Kura Oncology (KURA) shares does the insider own after these transactions?

After the reported transactions, Thomas Doyle beneficially owns 130,257 shares directly and 500 shares indirectly through his spouse's 401(k).

Why did the Kura Oncology (KURA) executive sell 4,539 shares?

The 4,539-share sale was described as a sell-to-cover for taxes related to the vesting of performance-based restricted stock units tied to a development milestone achieved on November 13, 2025.

What triggered the vesting of Kura Oncology (KURA) performance-based restricted stock units?

The filing states that performance criteria for one specified development milestone were determined to be met on November 13, 2025, causing 1/6th of the underlying PSU shares to vest.